Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
China’s BeiGene plans biologics plant
by Jean-François Tremblay
March 13, 2017
| A version of this story appeared in
Volume 95, Issue 11
Beijing-based oncology drug discovery firm BeiGene is joining with the government of Guangzhou in southern China to build a $330 million biologic drug facility in the Guangzhou Development District. The venture will also fund biologic drug R&D in China. Under the agreement, $30 million will come from BeiGene and $150 million from Guangzhou. The venture will borrow the rest. BeiGene says it needs large-scale manufacturing facilities to ensure growth.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter